Studies related to Immunity and Lactobacillus reuteri

Safety And Tolerability Of Lactobacillus Reuteri DSM 17938 And Effects On Biomarkers In Healthy Adults: Results From A Randomized Masked Trial

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 31
Gender Both Genders
Age Range 30-44
Body Types Overweight
Notes for this study:
In otherwise healthy adults given _l. reuteri_ DSM 17938 at 5x10^8^ CFU daily for two months was not associated with any severe side-effects and was well tolerated. Increases in fecal _l. reuteri_ were minimal in this study and not significantly different than placebo, and immune parameters (lymphocytes, monocytes, dendritic cells) were unaffected.